HomeNewsBusinessStocksBuy Syngene International; target of Rs 710: ICICI Direct
Trending Topics

Buy Syngene International; target of Rs 710: ICICI Direct

ICICI Direct is bullish on Syngene International recommended buy rating on the stock with a target price of Rs 710 in its research report dated January 21, 2022.

March 01, 2022 / 10:56 IST
Story continues below Advertisement

ICICI Direct's research report on Syngene International

Syngene is a contract research, development and manufacturing organisation catering mainly to global innovator pharma\chemical companies offering integrated scientific services from early discovery to commercial supply. • Syngene serves these players, which outsource some or substantial part of their business in the product development life cycle and operates via full time equipment (FTE) and fee for services (FFS) models • Revenue breakup: Discovery services (35%): FTE engagements with high renewability; Dedicated services (32%): Long-term strategic alliances that last usually five years or more, Development and manufacturing (33%): FFS engagements which increase in volume/scale over time.

Story continues below Advertisement

Outlook

Due to the structural story of outsourcing besides significant visibility capex and client stickiness, we remain positive and retain our BUY rating. We value Syngene at Rs 710 i.e. 40x FY24E EPS of Rs17.8.